Asset
Marnetegragene Autotemcel
Rocket Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03812263 | phase1_2 | completed | 2019-08-30 | 2023-09-12 | Rocket Pharmaceuticals Inc. | A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I |
| NCT03825783 | phase1 | withdrawn | 2019-04-15 | 2021-10-01 | Rocket Pharmaceuticals Inc. | A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 125806 | BLA | Rocket Pharmaceuticals Inc |
Marketed products (1)
- kresladi